Screen Reader Access   

People : Scientific : Faculty & Scientists

DR. ARUP BANERJEE, Ph.D. 

Adjunct Faculty
+91-129-2876325  (09650328080)
banerjeea [at] thsti [dot] res [dot] in
PhD (Science): Jadavpur University, Kolkata, India
M.Sc (Biochemistry): University of Calcutta, India
B.Sc (Chemistry): University of Calcutta, India

Present Research Interest

Currently, I am engaged in developing a collaborative project with International Vaccine Institute (IVI) Seoul, South Korea and BIBCOL (Bharat Immunologicals and Biologicals Corporation Limited, Bulandshahr, Uttar Pradesh). The project is related to the production of safe and effective oral cholera vaccine of global GMP standards in India. India is considered endemic cholera country and estimated to have 675,000 cholera cases and 20,000 deaths in 2015 which is constitutes 24% and 21% of estimated global cholera cases and deaths respectively. An outbreak review in India reported 21of 35 states reported cholera cases during at least one year between 1997 and 2006 which was six times higher than the cholera cases reported to WHO at the same time. The studies conducted in Kolkata showed that hospitalization cost of cholera illness is about 21% of the monthly household income. When looked at the national level, economic burden due to cholera treatment, loss of income due to inability to work and deaths are estimated to be more than $830 million in US$2015. Fortunately, there are vaccines available that can confer a significant reduction in cholera disease and deaths when used in conjunction with long-term effort to improve water and sanitation.

The WHO vaccine position paper has reiterated the use of OCV in outbreak controls and high-risk populations in endemic countries. The recent global disease burden study estimated more than 375 million high-risk populations in India who may warrant OCV use. Considering the optimal two dose approach and vaccine wastage, the number of doses required to cover such a large population is enormous compared to the number of OCV doses produced domestically in India.  The vaccine supply capacity of domestic manufacturer Shanta Biotechnics is believed to be around two million doses, and a significant portion of it is alleged to be pre-committed to global vaccine stockpile to be used elsewhere in the world as appropriate. This puts India in a difficult situation of “penury in the midst of plenty,” a country with highest estimated disease burden and having a licensed and WHO prequalified vaccine, but unavailable for domestic use. This warrants an urgent need for the scale-up of the OCV production in India for domestic use so that vaccine can be targeted to the neediest at the right time.

The purpose of the project is to make India capable of producing Oral Cholera Vaccine (OCV) to global GMP standards to meet its own supply needs in support of its National Cholera Control and Elimination Plan. 

  • Recent Publications: As PI

     

    1. Himani Sharma, Aarti Tripathi, Bharti Kumari, Sudhanshu Vrati, Arup Banerjee. Artificial microRNA mediated inhibition of Japanese Encephalitis Virus replication in neuronal cells. Nucleic Acid Therapeutics,(Accepted) 2018
    2. Pandey AD, Goswami S, Shukla S, Das S, Ghosal S, Pal M, Bandyopadhyay B, Ramachandran V, Basu N, Sood V, Pandey P, Chakrabarti J, Vrati S, Banerjee A.  Correlation of altered expression of a long non-coding RNA, NEAT1, in peripheral blood mononuclear cells with dengue disease progression. J Infect. 2017 Oct 12. pii: S0163-4453(17)30308-0. doi: 10.1016/j.jinf.2017.09.016. [Epub ahead of print]
      PMID:
       
      29031635
    3. Banerjee A,Shukla S, Pandey AD, Goswami S, Bandyopadhyay S,Ramachandran V, Das S, Malhotra A, Agarwal A, Adhikari S, Rahman M, Chatterjee S, Bhattacharya N, Basu N, Pandey P,Sood V, Vrati S.  RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with disease progression in dengue patients.Translational Research, 2017 Aug;186:62-78.e9. doi: 10.1016/j.trsl.2017.06.007.
    4. Pareek S, Roy S, Kumari B, Jain P, Banerjee A, Vrati S. miR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses. J Neuroinflammation. 2014 May 29;11(1):97. PMID: 24885259,  DOI 10.1186/1742-2094-11-97
    5. Kumari B, Jain P, Das S, Ghosal S, Hazra B, Trivedi AC, Basu A, Chakrabarti J, Vrati S, BanerjeeA. Dynamic changes in global microRNAome and transcriptome reveal complex miRNA-mRNA regulated host response to Japanese Encephalitis Virus in microglial cells. Scientific Reports 2016Feb 3;6:20263. doi: 10.1038/srep20263, PMID:26838068
    6. Goswami S, Banerjee A, Kumari B, Bandopadhyay B, Bhattacharya N, Basu N, Vrati S,Arup Banerjee.Differential expression and significance of circulating microRNAs in cerebrospinal fluid of acute encephalitis patients infected with Japanese Encephalitis Virus. Molecular Neurobiology (2016)PMID: 26860411  PMID: 26860411, DOI: 10.1007/s12035-016-9764-y

Publications: As Co-PI

5.    Sarkar N, Panigrahi R, PalA,  Biswas A,  Singh SP, Kar S,  BandopadhyayM,  DasD,  Saha D, Kanda T,  Sugiyama M,   Chakrabarti S,  Banerjee A,  Chakravarty R. Expression of microRNA-155 correlates positively with the expression of Toll Like Receptor 7 and modulates Hepatitis B Virus via C/EBP-β in Hepatocytes.J Viral Hepatitis 2015Oct;22(10):817-27.

6.     BandopadhyayM, Banerjee A, Sarkar N, Panigrahi R, Datta S, Pal A, Singh SP, Biswas A, Chakrabarti S, Chakravarty R. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC Cancer. 2014 Sep 26;14:721.

7.  Pal A, Panigrahi R, Biswas A, Datta S, Sarkar N, Guha SK, Saha B, Banerjee A,        Chakrabarti S, Chakravarty R. Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients. Virology. 2013, 436:134-42. 

1.     Panigrahi R, Biswas A, Banerjee A, Singh SP, Panigrahi MK, Roque-Afonso AM, Das HS, Mahapatra PK, Chakrabarti S, Chakravarty R. Subgenotype D5, BCP and MHR mutations in hepatic complications among hepatitis B virus infected patients from Orissa, India. Infect Genet Evol. 2012 Dec;12(8):1622-9. IF: 3.015 Cited by: 6

2.     Biswas A, Panigrahi R, Banerjee A, Pal M, De BK, Chakrabarti S, Chakravarty R. Differential pattern of pre-S mutations/deletions and its association with hepatitis B virus genotypes in Eastern India. Infect Genet Evol. 2012 Mar;12(2):384-91. IF: 3.015 Cited by: 10

3.     Panigrahi R, Majumder S, Gooptu M, Biswas A, Datta S, Chandra PK, Banerjee A, Chakrabarti S, Bandopadhyay D, De BK, Chakravarty R. Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India. Ann Hepatol. 2012 Nov-Dec;11(6):870-5.

2011

4.     Banerjee A,Mazumdar B, Meyer K, Di BisceglieAM, Ray RB, Ray R. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol.2011; 85:4157-66. Cited by: 25

5.     Mazumdar B, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology.2011, 54:1149-56. Cited by: 31

6.     Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One. 2011;6(8):e23699. Cited by: 16

7.     Biswas A, Banerjee A, Chandra PK, Datta S, Panigrahi R, Dutta D, De BK, Pal M, Guha SK, Chakrabarti S, Chakravarty R. Variations in the functional domain of basal core promoter of hepatitis B virus among Eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population. J Med Virol. 2011 Feb;83(2):253-60. Cited by: 11

2010

  1. Banerjee A,Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus infection differentially modulates activation of Fork-head transcription factors and insulin induced metabolic gene expression. J Virol. 2010,84:5936-46. Cited by: 32
  2. Ait-Goughoulte M, Banerjee A, Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus core protein interacts with fibrinogen-β and attenuates cytokine stimulated acute phase response. Hepatology 2010,51:1505-13. Cited by: 25
  3. Ray R, Meyer k, Banerjee A, Basu A, Houghton M, Frey S, and Belshe RB. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010,202:862-6. Cited by: 47
  4. Panigrahi R, Biswas A, Datta S, Banerjee A, Chandra PK, Mahapatra PK, Patnaik B. Chakrabarti S, Chakravarty R. Anti–hepatitis B core antigen testing with Detection and Characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam Southeastern India: implications for transfusion. Virology J. 2010,7:204. Cited by: 34

2009:

  1. Banerjee A,Saito K, Meyer K, Banerjee S, Ait-Goughoulte M, Ray RB, Ray R. Hepatitis C Virus Core Protein and Cellular Protein HAX-1 Promotes 5-Fluorouracil Mediated Hepatocyte Growth Inhibition. J Virol. 2009;83:9663-71. Cited by: 21
  2. Chandra PK, Biswas A, Datta S, Banerjee A, Panigrahi R, Chakrabarti S, Chakravarty R. Subgenotypes of Hepatitis B Virus Genotype D in India: differential pattern of mutations, liver injury and occult HBV infection. J Viral Hepatitis 2009;16:749–56.Cited by: 55
  3. Datta S, Panigrahi R, Biswas A, Chandra PK, Banerjee A, Mahapatra PK, Panda CK, Chakrabarti S, Bhattacharya SK, Biswas K, Chakravarty R. Genetic characterization of Hepatitis B Virus in peripheral blood leukocytes: Evidence for selection and compartmentalization of viral variants with immune escape G145R mutation. J Virol. 2009;83:9983-92.Cited by: 30
  4. Biswas A, Chandra PK, Datta S, Panigrahi R, Banerjee A, Chakrabarti S, Biswas K, Patra D, Bhattacharya P, Biswas K, Chakravarty R. Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors: Association with precore and basal core promoter mutations. Hepatol Res.2009;39:53-9. Cited by: 32

2008:

  1. Datta S, Banerjee A, Chandra PK, Biswas A, Panigrahi R, Mahapatra PK, Panda CK,  Chakrabarti S, Bhattacharya SK, Chakravarty R.  Analysis of hepatitis B virus X gene phylogeny, genetic variability and its impact on pathogenesis: implications in Eastern Indian HBV carriers. Virology2008;382:190-8. Cited by: 29
  2. Datta S, Biswas A, Chandra PK, Banerjee A,  Panigrahi R, Mahapatra PK, Chakrabarti S, Panda CK, Chakravarty R. Molecular epidemiology and clinical significance of hepatitis B virus genotypes, core promoter and precore mutations in Eastern India. Intervirology 2008;51:275-84.Cited by: 27

2007:

  1. Banerjee A,Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S, Basu SK, Chakravarty R. Frequency and Significance of Hepatitis B Virus Surface Gene Variant Circulating among ‘AntiHBc Only’ individuals in Eastern India. J Clin Virol. 2007; 40:312-7. Cited by: 49
  2. Datta S, Banerjee A, Chandra PK, Chakravarty R. Detection of a premature stop codon in the surface gene of hepatitis B virus from an HBsAg and antiHBc negative blood donor. . J Clin Virol. 2007;40:255-8. Cited by: 17
  3. Chandra PK, Banerjee A, Datta S, Chakravarty R. G1862T mutation among hepatitis B virus-infected individuals: association with viral genotypes and disease outcome in Kolkata, Eastern India.. Intervirology 2007;50:173-80.Cited by: 27
  4. Datta S, Chandra PK, Banerjee A, Chakravarty R, Murhekar KM, Murhekar MV. Predominance of Hepatitis B virus genotype C among Karens, the ‘old settlers’ of Andaman and Nicobar Islands, India. Arch Virol. 2007;152:1223-8.Cited by: 6
  5. Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, Basu SK, Chakravarty R. Significant increase in HIV, HBV, HCV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol. 2007;13:3730-3. Cited by: 152

2006:

  1. Banerjee A,Datta S, Chandra PK, Chowdhury A, Santra A, Roychowdhury S, Panda CK, Bhattacharya SK, Chakravarty R. Distribution of Hepatitis B Virus genotypes: Phylogenetic analysis and virological characteristics of Genotype C circulating among HBV carriers in Kolkata, Eastern India. World J Gastroenterol. 2006;12:5964-71.Cited by: 44
  2. Banerjee A, Kurvanob F, Datta S, Chandra PK, Tanaka Y, Mizokami M, Bhattacharya SK, Chakravarty R. Phylogenetic relatedness and genetic diversity of HBV genotype strain isolated from Eastern India. J Med Virol. 2006;78:1164-74. Cited by: 108
  3. Datta S, Banerjee A, Chandra PK, Mahapatra PK, Chakrabarti S, Chakravarty R. Drug trafficking routes and hepatitis B in injection drug users, Manipur, India. Emerg Infect Dis. 2006;12:1990-93.Cited by: 19
  4. Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol. 2006;78:53-9. Cited by: 65
  5. Murhekar MV, Chakravarty R, Murhekar KM, Banerjee A, Sehgal, SC. Hepatitis B Virus genotypes among the Jarwas: A primitive Negrito tribes of Andaman and Nicobar Islands, India. Arch Virol. 2006;151:1499-510. Cited by: 15

2005:

  1. Banerjee A,Banerjee S, Chowdhury A, Santra A, Chowdhury S, Roychowdhury S, Panda CK, Bhattacharya SK, Chakravarty R. Nucleic acid sequence analysis of basal core promoter/precore/core region of hepatitis B virus isolated from chronic carriers of the virus from Kolkata, eastern India: low frequency of mutation in the precore region. Intervirology 2005;48:389-99.
  2. Banerjee A, Chakravarty R, Mondal PN, Chakraborty MS. Hepatitis B virus genotype D infection among antenatal patients attending a maternity hospital in Calcutta, India: assessment of infectivity status. Southeast Asian J Trop Med Public Health. 2005;36:203-6. Cited by: 9
  3. Chowdhury A, Santra A, Chakravorty R, Banerjee A, Pal S, Dhali GK, Datta S, Banerji S, Manna B, Chowdhury SR, Bhattacharya SK, Mazumder DG. Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants. J Gastroenterol Hepatol. 2005;20:1712-20. Cited by: 62

Review article

  1. Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S, Banerjee A, Yokosuka O. Regulation of miRNA by HBV infection and their possible association with control of innate immunity. World J Gastroenterol, 2014, June 21; 20(23):7197-7206. Cited by: 14
  2. Banerjee A,Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Special issue: Cell transformation by viruses. Edited by: Dr Hung Fan and Dr Paul Lambert;  Viruses2010,2(9): 2108-33. Cited by: 43

 

Project: As Principal Investigator

Sl. No

Title of Project

Funding Agency

Amount (Lakhs)

Duration

1.

 Role of microRNAs in establishment of Japanese Encephalitis Virus (JEV) infection and disease progression

DBT, India

 

55.6

2013 –2016.

(completed) 

2.

Transcriptome analysis for identification of novel biomarker for disease progression in Dengue patients

 

DBT, India

140

2014-2018

(completed)

3.

Understanding the therapeutic role of adult stem cell-derived exosome in combating virus-induced neurodegenerative disease

DBT, India

87

Approved

(2018-2021)

 

4.

 

Investigating the molecular modulators of microglial activation and their effect on JEV pathogenesis

 

SERB, DST, India

 

 

Approved (2018-2021

 

 

  • Recipient of fellowship from ‘Viral Hepatitis Research Foundation of Japan’ in 2005 & 2011
  • ‘Guest Researcher’ at Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan; June 13 to 26, 2011.
  • Visiting fellow at  Nagoya City University Graduate School of Medical Science, Nagoya, Japan ; 13-27th February, 2005.
  • Recipient of DBT-CTEP Travel grant for participation in Keystone Symposium on Exosomes/Microvesicles: Novel Mechanisms of Cell-Cell Communications, held at Keystone, CO, June 19-22; 2016

MS. AARTI TRIPATHI
PH.D STUDENT

MS. NAINA SONI
JUNIOR RESEARCH FELLOW